Table 1 Relevant signal transduction inhibitors clinical trials in MDS
From: Signal transduction inhibitors in treatment of myelodysplastic syndromes
Family | Molecule | Trials |
|---|---|---|
P38 MAP kinase inhibitors | SCIO-469, ARRY- 614 | NCT00113893 NCT01496495 |
Activin and TGF- β receptor ligand trap | ACE- 011 & ACE 536 | NCT 01736683 NCT01432717 |
Multikinase Inhibitor (Plk/Akt/PI3) | Onconova-01910 | NCT00906334 |
P13K/mTOR inhibitors | Deferolimus, Temsirolimus, Everolimus, | NCT00819546 NCT00086125 NCT00809185 NCT01111448 |
P13K/AKT Inhibitors | Perifosine | NCT00301938 |
EGF Receptor Inhibitor | Erlotinib | NCT01085838 NCT00977548 |
GSTPI-1 inhibitor | Ezatiostat | NCT00700206 NCT01422486 NCT01459159 |
Farnesyl Transferase Inhibitors | Tipifarnib, Lonafarnib | NCT00005845 NCT00045396 NCT00050154 NCT00034684 NCT00005967 |
Mek Inhibitor | GSK1120212 | NCT00920140 |